Additionally, alterations in other genes involved in the MAPK pathway, such as the BRAF p. V600E mutation, the KRAS p. G12D mutation, or MET amplification, have been identified as mechanisms by which cancers can become resistant to TRK inhibition [64]. Here, NTRK1 is linked to cancer.